NOTE TO EDITORS: Further technology, corporate citizenship and executive news is available at www.agilent.com/go/news.
Agilent Technologies Inc. (NYSE: A) today introduced the new SureDirect Blood PCR Kit for amplification of DNA directly from blood and blood derivatives, without the need for nucleic acid extraction and isolation. This kit simplifies the DNA amplification workflow and decreases turn-around time by enabling PCR (polymerase chain reaction) directly from fresh, frozen and dried blood, as well as plasma and serum from human and animal samples. The Agilent SureDirect Blood PCR Kit includes the company’s latest novel inhibitor-resistant polymerase, DMSO, and positive control template and primers, providing the ability to overcome anti-coagulant and blood PCR inhibition and allowing for robust DNA target amplification even in high blood concentrations. Consistent amplification of GC-rich DNA targets and long amplicons are also achieved, giving researchers greater flexibility in experimental design. In addition, direct PCR from blood minimizes DNA yield loss from extraction and reduces the potential for sample mix-up and other potential sources of variation. “Agilent is pleased to offer the new SureDirect Blood PCR Kit to the international research community,” said Victor Fung, senior global marketing director of the Diagnostics and Genomics Group. “We are continually working to enhance our high-performance PCR products and are excited to add this innovative technology to our genomics portfolio.” Agilent’s molecular biology solutions include PCR instrumentation, high fidelity polymerases, and specialty enzymes, along with qPCR instrumentation and reagents, and market leading mutagenesis and cloning products. This new product further expands the capabilities of researchers and clinical researchers in applications which can benefit from direct DNA amplification from blood. About Agilent in Genomics Agilent is a global leader in target-enrichment solutions for next-generation sequencing and genomic microarrays. By synthesizing custom complex mixtures of long oligonucleotides, SureSelect and HaloPlex target-enrichment solutions enable researchers to identify genomic regions of interest for focused, cost-effective variant profiling, with workflows that generate sequencing-ready libraries in just one day. This core technology is the foundation for Agilent’s complete microarray-based solutions portfolio, which includes SurePrint technology for accurate genome-wide measurement of gene expression, arrayCGH for combined copy number assessment with SNP information, and SureFISH for highly sensitive and specific oligonucleotide fluorescent in-situ hybridization. Agilent also offers a microfluidic Bioanalyzer and TapeStation with complementary reagents and software for sample quantitation and quality assessment. For more information visit Agilent Genomics. About Agilent Technologies Agilent Technologies Inc. (NYSE: A) is the world’s premier measurement company and a technology leader in chemical analysis, life sciences, diagnostics, electronics and communications. The company’s 20,600 employees serve customers in more than 100 countries. Agilent had revenues of $6.8 billion in fiscal 2013. Information about Agilent is available at www.agilent.com. On Sept. 19, 2013, Agilent announced plans to separate into two publicly traded companies through a tax-free spinoff of its electronic measurement business. The new company is named Keysight Technologies, Inc. The separation is expected to be completed in early November 2014.